ARTICLE | Finance
Private biotechs halfway through valuation reset
51% of biotechs still haven’t raised new capital or advanced lead clinical asset since financing in 2020-22 period
January 25, 2025 12:28 AM UTC
The private biotech sector is about halfway through its valuation reset coming out of the 2020-22 period that saw biotechs raising record amounts of capital.
According to investors and bankers who spoke to BioCentury for the 2025 Financial Markets Preview, the valuations of private biotechs that raised capital in the 2020-22 period are often too high for what would be deemed a fair public market valuation now. ...